| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/06/2009 | EP2056111A1 Methods and compositions for regulating protein-protein interactions |
| 05/06/2009 | EP2055705A1 Compound having cyclic group bound thereto through spiro binding and use thereof |
| 05/06/2009 | EP2055302A1 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 05/06/2009 | EP2055300A2 Medicament comprising a C11-C21 alkanoic, alkenoic or alkynoic acid ester and a catechin |
| 05/06/2009 | EP2054062A1 Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs |
| 05/06/2009 | EP2054061A2 Combination therapy |
| 05/06/2009 | EP2054046A2 Compositions containing chalcones and use thereof |
| 05/06/2009 | EP1827500B1 Pegylated liposomal doxorubicin in combination with ecteinescidin 743 |
| 05/06/2009 | EP1807065A4 Methods and compositions for treating nephrogenic diabetes insipidus |
| 05/06/2009 | EP1628683B1 Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine |
| 05/06/2009 | EP1478398B1 New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors |
| 05/06/2009 | EP1410022B1 Detection and treatment of prostate cancer |
| 05/06/2009 | EP1385506B1 Acylated piperidine derivates as melanocortin-4 receptor agonists |
| 05/06/2009 | EP1272193B1 Synergistic combination therapy for treating cancer |
| 05/06/2009 | EP1242082B1 Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders |
| 05/06/2009 | EP1200114B1 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 05/06/2009 | EP1173155A4 Gum pad for delivery of medication to mucosal tissues |
| 05/06/2009 | EP1161248B1 Pharmaceutical composition containing nitrate source and an acidifying agent for treating open wound and burns |
| 05/06/2009 | CN101426934A Method of predicting skin spot formation and method of screening skin spot formation inhibitor with the use of spot site-increasing genes as indication |
| 05/06/2009 | CN101426903A Methods for identifying and targeting tumor stem cells based on nuclear morphology |
| 05/06/2009 | CN101426807A Neuroprotective compounds and uses thereof |
| 05/06/2009 | CN101426488A Stable oral pharmaceutical composition containing thyroid hormone receptor agonists |
| 05/06/2009 | CN101426480A Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion |
| 05/06/2009 | CN101423551A Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded; and uses thereof |
| 05/06/2009 | CN101422610A Chemical composite preparation and use thereof |
| 05/06/2009 | CN101422479A Compound injection medicine composite for treating pig, cattle respiratory disease |
| 05/06/2009 | CN100485035C Novel scavenger albumen receptors |
| 05/05/2009 | US7528252 Derivatives of triazoly-imidazopyridine useful as ligands of the adenosine A2a receptor and their use as medicaments |
| 05/05/2009 | US7528231 Kv10.1, a novel voltage-gated potassium channel from human brain |
| 05/05/2009 | US7528226 TGFβ1-inhibitor peptides |
| 05/05/2009 | US7528223 Polypeptide encoded by an alternative reading frame of an influenza virus |
| 05/05/2009 | US7528164 e.g. 2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-7-methyl-4H-pyrrolo [2,3-h]chromene; antiproliferative, antitumor, anticarcinogenic agent |
| 05/05/2009 | US7528149 e.g. N-[1-(2-aminoethyl)-4-piperidinyl]-7-methyl-3-(8-quinolinylmethyl)-3H-imidazo[4,5-b]pyridin-2-amine tetrahydrochloride trihydrate; immunostimulant; lower respiratory tract illness during infancy and childhood, asthma, pneumonia |
| 05/05/2009 | US7528137 Compounds, compositions, and methods |
| 05/05/2009 | US7528113 Method and composition for the treatment of adenoviral ocular infections |
| 05/05/2009 | US7528106 Angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor; peptide, pegaptanib sodium, EMD 472523; antiangiogenic drugs |
| 05/05/2009 | US7528093 Using genetic rearrangement in genomic region associated with brain voltage-gated sodium channel to detect convulsive disorder |
| 05/05/2009 | US7527969 Comprises purified imunoglobulin polypeptide or antigen binding fragment for diagnosis of disease/cancer |
| 05/05/2009 | US7527952 Crystals of inosine monophosphate dehydrogenase/oxidized inosine monophosphate thiomidate intermediate/mycophenolic acid (IIMPDH/XMP*/MPA) |
| 05/05/2009 | US7527810 Oral immunology using plant product containing hepatitis surface antigen |
| 05/05/2009 | US7527792 Arg-arg-leu-ser-tyr-ser-arg-arg-arg-phe decapeptide bonded to drug such as doxorubicin via maleimide derivative linkage; preventing chemoresistance or drug resistance; gene expression inhibition of multidrug resistance gene |
| 05/05/2009 | US7527790 Genetic engineered protein; screening, controlling gene expression |
| 05/05/2009 | CA2537402C Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| 05/05/2009 | CA2448281C Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
| 05/05/2009 | CA2436260C Compositions containing a ruthenium(iii) complex and a heterocycle |
| 05/05/2009 | CA2403352C Use of comt inhibitors as analgesics |
| 05/05/2009 | CA2386230C Modulators of cytokine mediated signalling pathways and integrin .alpha.v.beta.3 receptor antagonists for combination therapy |
| 05/05/2009 | CA2347863C Treatment of disorders of the outer retina |
| 05/05/2009 | CA2274116C Use, of an inhibitor of thioredoxin, for inhibiting tumor growth |
| 04/30/2009 | WO2009055824A1 Compositions and methods for treating asthma and lung disorders |
| 04/30/2009 | WO2009054544A1 Ampa receptor antagonists for parkinson's disease and movement disorders |
| 04/30/2009 | WO2009054463A1 Pharmaceutical composition containing lipophilic il-2 production inhibitor |
| 04/30/2009 | WO2009054454A1 Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient |
| 04/30/2009 | WO2009054332A1 Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| 04/30/2009 | WO2009052623A1 Therapeutic and diagnostic methods using tim-3 |
| 04/30/2009 | WO2009052617A1 Treatment regime for proliferative disorders |
| 04/30/2009 | WO2009027644A8 Compositions for the treatment of neoplastic diseases |
| 04/30/2009 | WO2008127594A3 Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer |
| 04/30/2009 | WO2008119042A3 Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease |
| 04/30/2009 | WO2008094969A3 Combination therapy with angiogenesis inhibitors |
| 04/30/2009 | WO2007095497A9 Compositions and methods for prevention and treatment of cachexia |
| 04/30/2009 | WO2006138610A3 Interferon-alpha/beta binding fusion proteins and therapeutic uses thereof |
| 04/30/2009 | WO2005102389A9 Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists |
| 04/30/2009 | WO2005070008A3 Polymer no donor predrug nanofiber coating for medical devices and therapy |
| 04/30/2009 | US20090111862 Compound |
| 04/30/2009 | US20090111812 Methods for treating inflammatory disorders |
| 04/30/2009 | US20090111792 Injectable capsaicin with tricyclic antidepressant adjunctive agent |
| 04/30/2009 | US20090111785 Combinations comprising antimuscarinic agents and corticosteroids |
| 04/30/2009 | US20090111744 Human Growth Gene and Short Stature Gene Region |
| 04/30/2009 | US20090110734 Quaternised ammonium cyclodextrin compounds |
| 04/30/2009 | US20090110687 Compositions and methods related to tim 3, a th1-specific cell surface molecule |
| 04/30/2009 | DE102007051339A1 Use of an aliphatic or aromatic hydrocarbon compound for manufacturing a preparation to prevent or treat dyslipidemia |
| 04/30/2009 | DE102007051338A1 Use of substituted glycerin derivatives for producing pharmaceutical preparation to prevent or treat isolated and/or combined dyslipidemia, hypertriglyceridemia and/or hypercholesterolemia, and for treating e.g. Parkinson's disease |
| 04/30/2009 | CA2703947A1 Therapeutic and diagnostic methods using tim-3 |
| 04/30/2009 | CA2703714A1 Compositions and methods for treating asthma and other lung disorders |
| 04/30/2009 | CA2703489A1 Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| 04/30/2009 | CA2699805A1 Treatment regime for proliferative disorders |
| 04/30/2009 | CA2609172A1 Immunotherapy compositions for use with targeted therapy in the treatment of cancer |
| 04/29/2009 | EP2053393A1 Pladienolide target molecule, compound capable of binding to the target molecule, and screening method for the compound |
| 04/29/2009 | EP2053135A1 Bone morphonic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma |
| 04/29/2009 | EP2053126A1 Streptococcus pneumoniae proteins and nucleic acid molecules |
| 04/29/2009 | EP2053038A1 Aminoalcohol derivative and immunosuppressant containing the same as an active ingredient |
| 04/29/2009 | EP2052739A1 Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient |
| 04/29/2009 | EP2052738A1 THERAPEUTIC AGENT FOR ACCELERATION OF SPINAL NERVE REPAIR COMPRISING GHRELIN, DERIVATIVE THEREOF OR SUBSTANCE CAPABLE OF ACTING ON GHS-R1a AS ACTIVE INGREDIENT |
| 04/29/2009 | EP2052714A1 Topical gel delivery systems for treating skin disorders |
| 04/29/2009 | EP2052697A1 Metering and packaging of controlled release medication |
| 04/29/2009 | EP2052251A1 Combination 5-ht7 receptor antagonist and serotonin reuptake inhibitor therapy |
| 04/29/2009 | EP2051987A2 Use of cd83 in combination therapies |
| 04/29/2009 | EP2051736A2 Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye |
| 04/29/2009 | EP2051735A2 Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof as well as their use in treating cns disorders |
| 04/29/2009 | EP2051732A1 Methods of diagnosis and treatment for metabolic disorders |
| 04/29/2009 | EP2051710A2 Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases |
| 04/29/2009 | EP2051583A2 Compositions and methods for treating vascular, autoimmune, and inflammatory diseases |
| 04/29/2009 | EP1572204B1 Synergistic compositions with analgesic properties comprising n-acylated 4-hydroxyphenylamine derivatives |
| 04/29/2009 | EP1454136B1 Methods and means for influencing intracellular communication and intracellular organelle transport |
| 04/29/2009 | EP1446379B1 Aryl aniline beta-2 adrenergic receptor agonists |
| 04/29/2009 | EP1383540B1 Methods and pharmaceutical compositions for healing wounds |
| 04/29/2009 | EP1343807B1 Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
| 04/29/2009 | EP1343475B1 Self forming, thermodynamically stable liposomes |
| 04/29/2009 | EP1304992B1 Topical gel delivery systems for treating skin disorders |